Wave life sciences announces publication of foundational preclinical data supporting development of wve-004 for c9orf72-associated als and ftd

Preclinical data published in molecular therapy nucleic acids demonstrate that wve-004 potently reduces c9orf72 transcriptional variants and poly(gp) dipeptide repeat proteins in mice for at least six months while maintaining c9orf72 protein levels
WVE Ratings Summary
WVE Quant Ranking